American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.06.9591PMID 16717289
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aprepitant

  2012cited by this paper
• Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

  2006cited by this paper
• In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.

  2006cited by this paper
• Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548–55.

  2006cited by this paper
• Drug Class Review on Newer Antiemetics

  2006cited by this paper
• The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

  2005cited by this paper
• Antiemetics in children receiving chemotherapy

  2005cited by this paper
• Antiemetics in children receiving chemotherapy

  2005cited by this paper
• Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

  2005cited by this paper
• The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants

  2005cited by this paper
• Comparison of aprepitant combination regimen with 4-day ondansetron + 4-day dexamethasone for prevention of acute and delayed nausea/vomiting after cisplatin chemotherapy

  2005cited by this paper
• Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

  2005cited by this paper
• Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines

  2005cited by this paper
• Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

  2005influential reference
• The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

  2005influential reference
• Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update

  2005cited by this paper
• Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

  2005cited by this paper
• Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

  2005cited by this paper
• Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement

  2005cited by this paper
• Emesis induced by low or minimal emetic risk chemotherapy

  2005cited by this paper
• Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis

  2004cited by this paper
• Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:.

  2004cited by this paper
• Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia.

  2004cited by this paper
• Single-Dose Oral Granisetron Versus MultiDose Intravenous Ondansetron for Moderately Emetogenic Cyclophosphamide-Based Chemotherapy in Pediatric Outpatients with Acute Lymphoblastic Lukemia

  2004cited by this paper
• Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis

  2004cited by this paper
• Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

  2003influential reference
• Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

  2003cited by this paper
• Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting

  2003cited by this paper
• Tropisetron and Dexamethasone Administered Twice Daily for the Prevention of Acute Emesis in Patients Treated With Continuous Infusion of Cisplatin-Doxorubicin and High-Dose Ifosfamide Over 48, 24, and 120 Hours

  2003cited by this paper
• Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

  2003cited by this paper
• The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

  2003influential reference
• Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist

  2003cited by this paper
• Pharmacokinetics of granisetron in adults and children with malignant diseases.

  2001cited by this paper
• High dose chemotherapy

  2000cited by this paper
• Prevention of cisplatin-induced delayed emesis: still unsatisfactory

  2000cited by this paper
• A COMPARISON OF ORAL ONDANSETRON SYRUP OR INTRAVENOUS ONDANSETRON LOADING DOSE REGIMENS GIVEN IN COMBINATION WITH DEXAMETHASONE FOR THE PREVENTION OF NAUSEA AND EMESIS IN PEDIATRIC AND ADOLESCENT PATIENTS RECEIVING MODERATELY/HIGHLY EMETOGENIC CHEMOTHERAPY

  2000cited by this paper
• Stratified Administration of Serotonin 5-HT3 Receptor Antagonists (Setrons) for Chemotherapy-Induced Emesis

  2000cited by this paper
• Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.

  2000cited by this paper
• Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence.

  2000cited by this paper
• Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy‐induced nausea and vomiting

  2000cited by this paper
• Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

  1999cited by this paper
• Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.

  1999cited by this paper
• Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist.

  1999cited by this paper
• Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.

  1999cited by this paper
• Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

  1999cited by this paper
• Dietary fiber and colorectal cancer.

  1999cited by this paper
• Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist.

  1999cited by this paper
• Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study.

  1999cited by this paper
• Delayed emesis following anticancer chemotherapy

  1998cited by this paper
• Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.

  1998cited by this paper
• Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).

  1998cited by this paper
• Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.

  1998cited by this paper
• Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference

  1998cited by this paper
• The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

  1997cited by this paper
• A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis.

  1997cited by this paper
• Proposal for classifying the acute emetogenicity of cancer chemotherapy.

  1997cited by this paper
• Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

  1997cited by this paper
• An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting.

  1997cited by this paper
• Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.

  1997cited by this paper
• The ASCO experience with evidence-based clinical practice guidelines.

  1997cited by this paper
• Ondansetron in radiation therapy of brain tumor in children.

  1996cited by this paper
• 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.

  1996cited by this paper
• A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.

  1996cited by this paper
• Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy.

  1996cited by this paper
• Models, mechanisms and management of anticipatory nausea and emesis.

  1996cited by this paper
• Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.

  1995cited by this paper
• Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide.

  1995cited by this paper
• Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin‐based chemotherapy. A prospective randomized trial

  1995cited by this paper
• Granisetron in the prevention of irradiation-induced emesis.

  1995cited by this paper
• Delayed emesis following anticancer chemotherapy

  1994cited by this paper
• On the mechanism of radiation-induced emesis: the role of serotonin.

  1994cited by this paper
• The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron.

  1994cited by this paper
• Efficacy of Oral Ondansetron, A Selective Antagonist of 5‐HT3 Receptors, in the Treatment of Nausea and Vomiting Associated with Cyclophosphamide‐Based Chemotherapies

  1994cited by this paper
• Ondansetron for efficient emesis control during total body irradiation.

  1994cited by this paper
• Efficacy of Oral Ondansetron, A Selective Antagonist of 5-HT3 Receptors, in the Treatment of Nausea and Vomiting Associated with Cyclophosphamide-Based Chemotherapies

  1994cited by this paper
• A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy.

  1993cited by this paper
• Methodological issues in antiemetic studies

  1993cited by this paper
• Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.

  1993cited by this paper
• Radiation-induced emesis: effects of ondansetron.

  1992cited by this paper
• Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation.

  1992cited by this paper
• The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.

  1992cited by this paper
• Behavioural interventions and psychological aspects of care during chemotherapy.

  1992cited by this paper
• The use of ondansetron in patients receiving multiple-day cisplatin regimens.

  1992cited by this paper
• Methodology of antiemetic trials: a review.

  1991cited by this paper
• Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia.

  1991cited by this paper
• Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.

  1991cited by this paper
• Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics.

  1991cited by this paper
• Predictive Factors of Delayed Emesis in Cisplatin‐Treated Patients and Antiemetic Activity and Tolerability of Metoclopramide or Dexamethasone: A Randomized Single‐Blind Study

  1991cited by this paper
• Methodology in anti-emetic trials.

  1991cited by this paper
• Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.

  1990cited by this paper
• Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

  1990cited by this paper
• Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

  1990cited by this paper
• Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population.

  1989cited by this paper
• Chemotherapy‐related nausea and vomiting: Etiology and management

  1989cited by this paper
• Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

  1989cited by this paper
• Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients.

  1989cited by this paper
• Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer

  1988cited by this paper
• Anticipatory nausea.

  1988cited by this paper
• Vomiting associated with whole body irradiation.

  1987cited by this paper
• A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea.

  1987cited by this paper

• Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis

  2025cites this paper
• A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies.

  2025cites this paper
• Therapeutic Dose of Metoclopramide Induced Dystonic Reacton in Children

  2024cites this paper
• Enhancing global hepatocellular carcinoma management: Bridging Eastern and Western perspectives on dexamethasone and N-acetylcysteine before transarterial chemoembolization

  2024cites this paper
• Bibliometric and visual analysis of chemotherapy-induced nausea and vomiting (2004-2023)

  2024cites this paper
• Portuguese consensus on the prevention and treatment of nausea and vomiting induced by cancer treatments

  2023cites this paper
• Research progress on the premature ovarian failure caused by cisplatin therapy

  2023cites this paper
• Chemotherapy-induced gastrointestinal toxicity: Pathogenesis and current management.

  2023cites this paper
• Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review

  2023cites this paper
• Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation

  2023cites this paper
• The role of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) to assess the sensitivity to chemo drugs for gastric cancer in combination with other cancer therapeutic drugs.

  2022cites this paper
• Emetic Response to T-2 Toxin Correspond to Secretion of Glucagon-like Peptide-17–36 Amide and Glucose-Dependent Insulinotropic Polypeptide

  2022cites this paper
• Oral Therapies for Multiple Myeloma

  2022cites this paper
• Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

  2022cites this paper
• Evaluation of Sex Differences in the Potential of Δ9-Tetrahydrocannabinol, Cannabidiol, Cannabidiolic Acid, and Oleoyl Alanine to Reduce Nausea-Induced Conditioned Gaping Reactions in Sprague-Dawley Rats

  2022cites this paper
• The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy

  2022cites this paper
• Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma

  2021cites this paper
• Gastric side effects and the stomach dosimetric analysis in left-sided breast cancer radiotherapy in free-breathing and deep inspiration breath-hold technique

  2021cites this paper
• Chemotherapy-Induced Nausea and Vomiting

  2021cites this paper
• Dexamethasone prevents TACE-induced adverse events

  2020cites this paper
• Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

  2020cites this paper
• Upregulation of the long noncoding RNAs DSCAM‐AS1 and MANCR is a potential diagnostic marker for breast carcinoma

  2020cites this paper
• ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE

  2020cites this paper
• Nežádoucí účinky chemoterapie

  2020cites this paper
• Cannabis et cancer : à la veille de l’expérimentation française du cannabis thérapeutique, de quelles données disposons-nous sur ses propriétés thérapeutiques et ses dangers ?

  2020cites this paper
• Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs

  2020cites this paper
• Antiemetics: ASCO Guideline Update.

  2020cites this paper
• Профилактика и лечение тошноты и рвоты у детей и подростков, получающих противоопухолевую терапию. Текущее состояние и потенциальные пути улучшения

  2020cites this paper
• Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults

  2020cites this paper
• Pharmacokinetics and Safety of Fosaprepitant Dimeglumine in Healthy Chinese Volunteers: Bioequivalence Study

  2020cites this paper
• [Prevention and treatment of antineoplastic drug-induced nausea and vomiting in pediatric onco-hematology: An update].

  2020cites this paper
• The prevention and treatment of chemotherapy-induced nausea and vomiting in children and adolescents receiving cancer treatment: the current status and possibilities for improvement

  2020cites this paper
• Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety.

  2020cites this paper
• BIOAVAILABILITY STUDY OF ONDANSETRON GEL IN RABBITS AND HUMAN VOLUNTEERS APPLING UPLC AS ANALYTICAL TOOL AND EVALUATION OF THE ANTIEMETIC EFFECT OF ONDANSETRON GEL IN CISPLATIN-INDUCED EMESIS IN RATS

  2020cites this paper
• Nanotechnology based blended chitosan-pectin hybrid for safe and efficient consolidative antiemetic and neuro-protective effect of meclizine hydrochloride in chemotherapy induced emesis.

  2020cites this paper
• Expression Analysis of EEPD1 and MUS81 Genes in Breast Cancer

  2020cites this paper
• Modulation of the 5-HT3A receptor current by desacylbaldrinal

  2019cites this paper
• Latest Update on Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients

  2019cites this paper
• Measures for Adverse Events and Outpatient Chemotherapy of S-1+Cisplatin for Unresectable Progressive Recurrent Gastric Cancer

  2019cites this paper
• Nebenwirkungen und Komplikationen der medikamentösen Schmerztherapie

  2019cites this paper
• Pharmacology of Postoperative Nausea and Vomiting

  2019cites this paper
• Cisplatin: The first metal based anticancer drug.

  2019cites this paper
• Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults

  2019cites this paper
• Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting

  2019cites this paper
• A retrospective case cohort analysis on the clinical utility of fosaprepitant in CINV prophylaxis in day care center of South India

  2019cites this paper
• Supporting Clinical Decision Making in Cancer Care Delivery

  2019cites this paper
• 切除不能進行再発胃癌に対するS-1＋シスプラチン療法の有害事象対策と外来化学療法

  2019cites this paper
• Chemotherapy-Induced Nausea/Vomiting (CINV)

  2019cites this paper
• Endocrine and Metabolic Disorders After Hematopoietic Stem Cell Transplantation Annalisa Paviglianiti Metabolic Diseases in Hematology

  2019cites this paper
• Endocrine and Metabolic Disorders after Hematopoietic Cell Transplantation

  2019cites this paper
• Nonpain Symptom Management.

  2019cites this paper
• Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large‐scale administrative database

  2019cites this paper
• Analysis of Dietary Intake during Consecutive-Day Chemotherapy for Bone and Soft-Tissue Sarcomas

  2018cites this paper
• A Comparative Safety Profile Assessment of Oncolytic Virus Therapy Based on Clinical Trials

  2018cites this paper
• Correspondence

  2018cites this paper
• Efficacy and Safety of Aprepitant in Combination with Dexamethasone, Granisetron and Metoclopramide as a Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in a Acute and Delayed Emesis in Arab Cancer Patient

  2018cites this paper
• A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting

  2018cites this paper
• Оценка эффективности апрепитанта для профилактики тошноты и рвоты у больных раком молочной железы

  2018cites this paper
• First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors

  2018cites this paper
• Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl

  2018cites this paper
• Guía de práctica clínica sobre cuidados paliativos

  2018cites this paper
• Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database

  2018cites this paper
• Transplanting Hepatitis C–Seropositive, Nucleic Acid Test–Negative Donor Organs Into Hepatitis C–Negative Recipients

  2018cites this paper
• Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies

  2018cites this paper
• Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia

  2018cites this paper
• A prospective cohort study of patient-reported vomiting, retching, nausea and antiemetic use during neoadjuvant long-course radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal adenocarcinoma

  2018cites this paper
• A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy

  2018cites this paper
• S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial

  2018cites this paper
• The Use of Steroid for Transcatheter Arterial Chemoembolization: To Relieve Symptoms or to Mask Adverse Events?

  2018cites this paper
• Direct modification of the 5‐HT3 receptor current by some anticancer drugs

  2018cites this paper
• Prevention of post-embolization syndrome after transarterial chemoembolization for hepatocellular carcinoma-is prophylactic dexamethasone useful, or not?

  2018cites this paper
• A randomized placebo‐controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization

  2018cites this paper
• 20 – Palliative Care and Quality of Life

  2018cites this paper
• In Vitro Chemosensitivity Test for Gastric Cancer Specimens Predicts Effectiveness of Oxaliplatin and 5-Fluorouracil.

  2017cites this paper
• Synthetic and natural antioxidants attenuate cisplatin-induced vomiting

  2017cites this paper
• Erratum to: Synthetic and natural antioxidants attenuate cisplatin-induced vomiting

  2017cites this paper
• Effects of chemotherapy on the health-related quality of life of Japanese lower rectal cancer patients after sphincter-saving surgery

  2017cites this paper
• A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy

  2017cites this paper
• Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

  2017cites this paper
• A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed‐phase CINV associated with TC therapy in gynaecological cancer

  2017cites this paper
• Tratamiento psicológico de la emesis anticipatoria

  2017cites this paper
• Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2017cites this paper
• Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)

  2017cites this paper
• Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy

  2017cites this paper
• Multiparticulate Technologies for Fixed-Dose Combinations

  2017cites this paper
• СХЕМА ХИМИОТЕРАПИИ AC (ДОКСОРУБИЦИН И ЦИКЛОФОСФАМИД) ПРИ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ ПРОФИЛАКТИКА ТОШНОТЫ И РВОТЫ

  2017cites this paper
• Title Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer

  2017cites this paper
• Moxibustion for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis

  2017cites this paper
• Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer

  2017cites this paper
• Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT)

  2017cites this paper
• Pharmacology of Antiemetics: Update and Current Considerations in Anesthesia Practice.

  2017cites this paper
• Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia.

  2017cites this paper
• Challenges and Opportunities for Occupational Epidemiology in the Twenty-first Century

  2017cites this paper
• NCCN Guidelines Insights: Antiemesis, Version 2.2017.

  2017cites this paper
• An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects.

  2016cites this paper
• Delayed Nausea/Emesis

  2016cites this paper
• Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by the CINV Study Group of Japan.

  2016cites this paper
• Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy

  2016cites this paper
• The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India

  2016cites this paper
• Antiemetics: American Society of Clinical Oncology Focused Guideline Update.

  2016cites this paper